Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asra Husain

Neurology Valley Stream, NY Doctor of Osteopathy

NPI 1275795387 CMS profile 240132

1129 Linden St, Valley Stream, NY 11580

Open in the dashboard

General payments

$34,103

807 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asra Husain of Valley Stream, NY is reported in the CMS Open Payments database as having received $34,103 across 807 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,795 44
2024 General $11,528 168
2023 General $8,429 163
2022 General $3,444 153
2021 General $2,380 118
2020 General $1,642 84
2019 General $1,886 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asra Husain
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Asra Husain were reported at $4,795. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Asra Husain Neurology median Middle half National median
2019 $1,886 $474 $118–$2,177 $163
2020 $1,642 $367 $82–$2,309 $114
2021 $2,380 $438 $104–$2,547 $132
2022 $3,444 $442 $103–$2,388 $149
2023 $8,429 $464 $119–$2,312 $160
2024 $11,528 $468 $119–$2,323 $164
2025 $4,795 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $18,932 86 payments
  2. SK Life Science, Inc. $1,560 72 payments
  3. UCB, Inc. $1,356 67 payments
  4. Biogen, Inc. $1,262 62 payments
  5. Eisai Inc. $1,191 34 payments
  6. Genentech USA, Inc. $909 55 payments
  7. Lilly USA, LLC $653 25 payments
  8. Novartis Pharmaceuticals Corporation $617 35 payments
  9. EMD Serono, Inc. $588 29 payments
  10. Neurelis, Inc. $576 21 payments
  11. Other $6,459 321 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,235 795 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,675 9 payments
  3. Education $193 3 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $18,022 47 payments
  2. UBRELVY $5,845 35 payments
  3. Briviact $1,106 57 payments
  4. Fycompa $903 20 payments
  5. OCREVUS $780 47 payments
  6. TYSABRI $709 31 payments
  7. APTIOM $614 32 payments
  8. VALTOCO $576 21 payments
  9. BRIUMVI $432 15 payments
  10. ZEPOSIA $421 16 payments
  11. Other $8,689 451 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,291

Median for Neurology: 833

Drug cost

$883,963

Median for Neurology: $202,670

Branded share of claims

34.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 11 $290,221
Zeposia Ozanimod Hydrochloride Brand 13 $153,430
Nuplazid Pimavanserin Tartrate Brand 16 $137,480
Qulipta Atogepant Brand 73 $79,084
Xcopri Cenobamate Brand 34 $39,428
Botox Onabotulinumtoxina Brand 26 $38,683
Nurtec Odt Rimegepant Sulfate Brand 13 $24,000
Aptiom Eslicarbazepine Acetate Brand 16 $21,237
Dalfampridine Er Dalfampridine Brand 17 $20,772
Briviact Brivaracetam Brand 13 $18,358

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$106,975

Medicare's payments for the services billed

Medicare patients

526

Average age 76

Services billed

1,343

308 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 62%
Ischemic heart disease 51%
Chronic kidney disease 50%
Alzheimer's or dementia 45%
Depression 39%
Heart failure 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$8,423 73 —
VALTOCO
$297 — —
Briviact
$256 13 —
KISUNLA
$186 — —
BRIUMVI
$165 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

807 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record